{"id":996851,"date":"2026-08-20T07:03:24","date_gmt":"2026-08-20T11:03:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\/"},"modified":"2026-08-20T07:03:24","modified_gmt":"2026-08-20T11:03:24","slug":"ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\/","title":{"rendered":"Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistcircle { list-style-type: circle }\n.bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026<\/b><\/p>\n<p>CARLSBAD, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fionis.com%2F&amp;esheet=54592208&amp;newsitemid=20260820195483&amp;lan=en-US&amp;anchor=Ionis+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=6357ce1e5d4740dc7c22efd22a2cfabd\">Ionis Pharmaceuticals, Inc.<\/a> (Nasdaq: IONS) today announced that new data in the management of severe hypertriglyceridemia (sHTG) will be presented at the European Society of Cardiology (ESC)\u00a0Congress 2026, taking place August 28 \u2013 31 in Munich. Presentations include one-year data from the open-label, long-term extension study of TRYNGOLZA\u00ae (olezarsen), recently approved in the U.S. as the first and only treatment for sHTG to reduce triglycerides and the risk of acute pancreatitis, and Phase 1 data in hypertriglyceridemia for ION775, an investigational siRNA and next-generation follow-on to TRYNGOLZA with the potential for semiannual or less frequent dosing.<\/p>\n<p>\n\u201cPeople living with sHTG face the risk of potentially life-threatening acute pancreatitis attacks, which can cause prolonged and recurrent hospitalizations and organ failure, underscoring the urgency to lower triglycerides below the guideline-recommended levels,\u201d said Sam Tsimikas, M.D., senior vice president, global cardiovascular development, Ionis. \u201cThe recent approval of TRYNGOLZA, the first and only approved treatment for sHTG to reduce triglycerides and the risk of acute pancreatitis, highlights Ionis\u2019 leadership in sHTG and marks a new era in the management of this serious disease. The data being presented at the ESC Congress further reinforce our leadership and commitment in the field as we advance science and innovative medicines with the potential to transform the lives of people living with sHTG.\u201d<\/p>\n<p>\nTRYNGOLZA was <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.ionis.com%2Fnews-releases%2Fnews-release-details%2Ftryngolzar-olezarsen-approved-fda-first-and-only-treatment&amp;esheet=54592208&amp;newsitemid=20260820195483&amp;lan=en-US&amp;anchor=approved&amp;index=2&amp;md5=2d873752e0ebdb1dfde97152cd531a6d\">approved<\/a> by the U.S. Food and Drug Administration for sHTG in June 2026. An indication extension application for TRYNGOLZA in sHTG is under review by the European Medicines Agency, with Sobi holding commercialization rights in the EU. ION775 is in development for sHTG and is currently being investigated in a Phase 2 study.<\/p>\n<p><b>Key Presentation Details:<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nLong-term efficacy and safety of olezarsen in patients with severe hypertriglyceridemia<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nOral Presentation: Friday, August 28, 8:33 \u2013 8:57 a.m. CEST<\/p>\n<\/li>\n<li>\nPresenting Author: Robert Giugliano, M.D.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nION775, a long-acting siRNA targeting APOC3: single-dose, 12-month results in participants with moderate hypertriglyceridemia<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nOral Presentation: Friday, August 28, 11:35 \u2013 11:45 a.m. CEST<\/p>\n<\/li>\n<li>\nPresenting Author: Sotirios (Sam) Tsimikas, M.D.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\nAdditionally, Ionis and partner AstraZeneca will present data from the CARDIO-TTRansform Phase 3 trial of eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Presentations include a detailed analysis of the Phase 3 data and a subgroup analysis of eplontersen in patients receiving stabilizer treatment. A meta-analysis of eplontersen and another silencer therapy in combination with stabilizers in ATTR-CM will also be presented by an independent academic group.<\/p>\n<p>\nPresentations will be available on the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fionis.com%2Fscientific-publications&amp;esheet=54592208&amp;newsitemid=20260820195483&amp;lan=en-US&amp;anchor=Ionis+website&amp;index=3&amp;md5=db80364d6222ec636d2ae74171a2a3f4\">Ionis website<\/a> once each embargo lifts.<\/p>\n<p><b>INDICATIONS<\/b><\/p>\n<p><span class=\"bwuline\">Familial Chylomicronemia Syndrome (FCS)<br \/>\n<br \/><\/span>TRYNGOLZA (olezarsen) is indicated as an adjunct to diet to reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS).<\/p>\n<p><span class=\"bwuline\">Severe Hypertriglyceridemia (sHTG)<br \/>\n<br \/><\/span>TRYNGOLZA is indicated as an adjunct to diet to reduce TG and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG \u2265500 mg\/dL).<\/p>\n<p><b>IMPORTANT SAFETY INFORMATION<br \/>\n<br \/><\/b><b>CONTRAINDICATIONS<br \/>\n<br \/><\/b>TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred.<\/p>\n<p><b>WARNINGS AND PRECAUTIONS<br \/>\n<br \/><\/b><b>Hypersensitivity Reactions<br \/>\n<br \/><\/b>Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills, and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur.<\/p>\n<p><b>Liver Enzyme Abnormalities<br \/>\n<br \/><\/b>TRYNGOLZA can cause increases in liver enzymes and hepatic fat in adults. Increases in liver enzymes were more frequently reported with the 80 mg dose as compared with the 50 mg dose. Consider liver enzyme testing before TRYNGOLZA initiation or an increase in dosage and when clinically indicated thereafter. If persistent elevations in liver enzymes occur, consider dose interruption and\/or dose reduction. If serious hepatic injury with clinical symptoms and\/or hyperbilirubinemia or jaundice occurs, promptly discontinue TRYNGOLZA.<\/p>\n<p><b>ADVERSE REACTIONS<br \/>\n<br \/><\/b><span class=\"bwuline\">Adverse Reactions for FCS<br \/>\n<br \/><\/span>Most common adverse reactions in patients with FCS (incidence &gt;5% of TRYNGOLZA-treated patients and &gt;3% higher frequency than placebo) were injection site reactions, decreased platelet count, and arthralgia.<\/p>\n<p><span class=\"bwuline\">Adverse Reactions for sHTG<br \/>\n<br \/><\/span>Most common adverse reactions in patients with sHTG (incidence \u22652% higher than placebo) were injection site reactions and liver enzyme increases.<\/p>\n<p><b>Please see full <\/b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ionis.com%2Fmedicines%2FTRYNGOLZA%2FTRYNGOLZA-FPI.pdf&amp;esheet=54592208&amp;newsitemid=20260820195483&amp;lan=en-US&amp;anchor=Prescribing+Information&amp;index=4&amp;md5=91f470c203f6dd261bfabccf1a7c9bf2\"><b>Prescribing Information<\/b><\/a><b> for TRYNGOLZA. Please see Important Safety Information throughout and full <\/b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ionis.com%2Fmedicines%2FTRYNGOLZA%2FTRYNGOLZA-FPI.pdf&amp;esheet=54592208&amp;newsitemid=20260820195483&amp;lan=en-US&amp;anchor=Prescribing+Information&amp;index=5&amp;md5=270c16e6d4cbe5ba6f2451b4baede666\"><b>Prescribing Information<\/b><\/a><b> for TRYNGOLZA.<\/b><\/p>\n<p><b>About the CORE and CORE2 Studies<br \/>\n<br \/><\/b>CORE (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT05079919%3Fterm%3Dolezarsen%26rank%3D8&amp;esheet=54592208&amp;newsitemid=20260820195483&amp;lan=en-US&amp;anchor=NCT05079919&amp;index=6&amp;md5=353a45d707688b7d2d8b2428611cc02c\">NCT05079919<\/a>; n=617) and CORE2 (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT05552326%3Fterm%3Dolezarsen%26rank%3D7&amp;esheet=54592208&amp;newsitemid=20260820195483&amp;lan=en-US&amp;anchor=NCT05552326&amp;index=7&amp;md5=868bbf9fc60a841c6c829b78f8dda628\">NCT05552326<\/a>; n=446), conducted with The TIMI Study Group, are Phase 3 global, multicenter, randomized, double-blind, placebo-controlled trials investigating the safety and efficacy of olezarsen for severe hypertriglyceridemia (sHTG). Participants aged 18 and older with triglyceride levels \u2265500 mg\/dL were enrolled. Participants were required to be on standard of care therapies for elevated triglycerides. At baseline, 47% and 37% of participants had fasting triglycerides \u2265880 mg\/dL in CORE and CORE2, respectively. Participants were randomized to receive 50 mg or 80 mg of olezarsen or placebo every four weeks via subcutaneous injection for 12 months.<\/p>\n<p><b>About Severe Hypertriglyceridemia<br \/>\n<br \/><\/b>Severe hypertriglyceridemia (sHTG) is defined by very high triglycerides (\u2265500 mg\/dL) and characterized by an increased risk of acute pancreatitis and other serious health complications. Considered a medical emergency, acute pancreatitis causes debilitating abdominal pain that often requires prolonged hospitalization, can lead to permanent organ damage and can become life-threatening. Preventing the first attack is key. In people with a history of acute pancreatitis episodes, the risk of future attacks is even greater. Current standard of care therapies for sHTG and lifestyle modifications (such as diet and exercise) do not sufficiently or consistently lower triglyceride levels or reduce the risks of sHTG in all patients. More than 3 million people are living with sHTG in the U.S., including approximately 1 million who are considered high risk. High-risk sHTG includes those with triglycerides \u2265880 mg\/dL or triglycerides \u2265500 mg\/dL and a history of acute pancreatitis or other comorbidities.<\/p>\n<p><b>About TRYNGOLZA\u00ae (olezarsen)<br \/>\n<br \/><\/b>TRYNGOLZA\u00ae (olezarsen) is an RNA-targeted therapy designed to lower the body&#8217;s production of apoC-III, a protein produced in the liver that regulates triglyceride metabolism in the blood. TRYNGOLZA is approved in the United States as an adjunct to diet to reduce triglycerides (TG) and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG greater than or equal to 500 mg\/dL). TRYNGOLZA is also approved in the United States, European Union and other countries for adults with familial chylomicronemia syndrome (FCS), a rare form of sHTG. Visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftryngolza.com%2F&amp;esheet=54592208&amp;newsitemid=20260820195483&amp;lan=en-US&amp;anchor=TRYNGOLZA.com&amp;index=8&amp;md5=4b723ecd6ef675a6b4937392e9b56365\">TRYNGOLZA.com<\/a> for more information.<\/p>\n<p><b>About Ionis Pharmaceuticals, Inc.<br \/>\n<br \/><\/b>For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ionis.com%2F&amp;esheet=54592208&amp;newsitemid=20260820195483&amp;lan=en-US&amp;anchor=Ionis.com&amp;index=9&amp;md5=c47e3f88bf8e9c2f905fbc2cc2d2324d\">Ionis.com<\/a> and follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2Fionispharma&amp;esheet=54592208&amp;newsitemid=20260820195483&amp;lan=en-US&amp;anchor=X+%28Twitter%29&amp;index=10&amp;md5=3766e9fdbc6343f629f86f9aabcd7644\">X (Twitter)<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fionis-pharmaceuticals&amp;esheet=54592208&amp;newsitemid=20260820195483&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=11&amp;md5=56fc26f1ed09c60b9ebbf70bfb138607\">LinkedIn<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fionis_pharma%2F&amp;esheet=54592208&amp;newsitemid=20260820195483&amp;lan=en-US&amp;anchor=Instagram&amp;index=12&amp;md5=559d1704460ec2b8196e59fd364df33c\">Instagram<\/a>.<\/p>\n<p><b>Ionis Forward-looking Statements<br \/>\n<br \/><\/b>This press release includes forward-looking statements regarding Ionis&#8217; business and the therapeutic and commercial potential of TRYNGOLZA, ION775, Ionis&#8217; technologies and other products in development. Any statement describing Ionis&#8217; goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis&#8217; forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis&#8217; forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis&#8217; programs are described in additional detail in Ionis&#8217; annual report on Form 10-K for the year ended December 31, 2025, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company. In this press release, unless the context requires otherwise, &#8220;Ionis,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; all refer to Ionis Pharmaceuticals and its subsidiaries.<\/p>\n<p>\nIonis Pharmaceuticals<sup>\u00ae<\/sup> and TRYNGOLZA<sup>\u00ae<\/sup> are trademarks of Ionis Pharmaceuticals, Inc.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260820195483r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260820195483\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260820195483\/en\/<\/a><\/span><\/p>\n<p><b>Ionis Investor Contact:<br \/>\n<\/b><br \/>D. Wade Walke, Ph.D.<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:IR@ionis.com\">IR@ionis.com<\/a> 760-603-2331<\/p>\n<p><b>Ionis Media Contact:<br \/>\n<\/b><br \/>Hayley Soffer<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:media@ionis.com\">media@ionis.com<\/a> 760-603-4679<\/p>\n<p><b>KEYWORDS:<\/b> California Germany Europe United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Clinical Trials Research Science Pharmaceutical Cardiology Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260820195483\/en\/2366088\/3\/Ionis_Logo_RGB.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 CARLSBAD, Calif.&#8211;(BUSINESS WIRE)&#8211;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data in the management of severe hypertriglyceridemia (sHTG) will be presented at the European Society of Cardiology (ESC)\u00a0Congress 2026, taking place August 28 \u2013 31 in Munich. Presentations include one-year data from the open-label, long-term extension study of TRYNGOLZA\u00ae (olezarsen), recently approved in the U.S. as the first and only treatment for sHTG to reduce triglycerides and the risk of acute pancreatitis, and Phase 1 data in hypertriglyceridemia for ION775, an investigational siRNA and next-generation follow-on to TRYNGOLZA with the potential for semiannual or less frequent dosing. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-996851","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 CARLSBAD, Calif.&#8211;(BUSINESS WIRE)&#8211;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data in the management of severe hypertriglyceridemia (sHTG) will be presented at the European Society of Cardiology (ESC)\u00a0Congress 2026, taking place August 28 \u2013 31 in Munich. Presentations include one-year data from the open-label, long-term extension study of TRYNGOLZA\u00ae (olezarsen), recently approved in the U.S. as the first and only treatment for sHTG to reduce triglycerides and the risk of acute pancreatitis, and Phase 1 data in hypertriglyceridemia for ION775, an investigational siRNA and next-generation follow-on to TRYNGOLZA with the potential for semiannual or less frequent dosing. &hellip; Continue reading &quot;Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-20T11:03:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260820195483r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026\",\"datePublished\":\"2026-08-20T11:03:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\\\/\"},\"wordCount\":1507,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260820195483r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\\\/\",\"name\":\"Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260820195483r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-08-20T11:03:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260820195483r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260820195483r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\/","og_locale":"en_US","og_type":"article","og_title":"Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 - Market Newsdesk","og_description":"Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 CARLSBAD, Calif.&#8211;(BUSINESS WIRE)&#8211;Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data in the management of severe hypertriglyceridemia (sHTG) will be presented at the European Society of Cardiology (ESC)\u00a0Congress 2026, taking place August 28 \u2013 31 in Munich. Presentations include one-year data from the open-label, long-term extension study of TRYNGOLZA\u00ae (olezarsen), recently approved in the U.S. as the first and only treatment for sHTG to reduce triglycerides and the risk of acute pancreatitis, and Phase 1 data in hypertriglyceridemia for ION775, an investigational siRNA and next-generation follow-on to TRYNGOLZA with the potential for semiannual or less frequent dosing. &hellip; Continue reading \"Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-20T11:03:24+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260820195483r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026","datePublished":"2026-08-20T11:03:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\/"},"wordCount":1507,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260820195483r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\/","name":"Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260820195483r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-08-20T11:03:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260820195483r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260820195483r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ionis-to-present-new-data-strengthening-leadership-in-the-management-of-severe-hypertriglyceridemia-shtg-at-the-european-society-of-cardiology-congress-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/996851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=996851"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/996851\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=996851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=996851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=996851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}